Dendritic cell immunotherapy: mapping the way
- PMID: 15122249
- DOI: 10.1038/nm1039
Dendritic cell immunotherapy: mapping the way
Abstract
Dendritic cells (DCs) are the professional antigen-presenting cells of the immune system, with the potential to either stimulate or inhibit immune responses. Exploiting the immune-regulatory capacities of dendritic cells holds great promise for the treatment of cancer, autoimmune diseases and the prevention of transplant rejection. Although early clinical trials indicate that DC vaccines can induce immune responses in some cancer patients, careful study design and use of standardized clinical and immunological criteria are needed.
Similar articles
-
Optimizing dendritic cell-based immunotherapy for cancer.Expert Rev Vaccines. 2007 Jun;6(3):333-45. doi: 10.1586/14760584.6.3.333. Expert Rev Vaccines. 2007. PMID: 17542749
-
Dendritic cells and their role in cancer immunotherapy.Iran J Immunol. 2007 Sep;4(3):127-44. Iran J Immunol. 2007. PMID: 17767012 Review.
-
[Dendritic cells: orchestration of the immune response].Ann Biol Clin (Paris). 2000 Sep-Oct;58(5):541-56. Ann Biol Clin (Paris). 2000. PMID: 11022098 Review. French.
-
Cellular immunotherapy with dendritic cells in cancer: current status.Stem Cells. 2004;22(4):501-13. doi: 10.1634/stemcells.22-4-501. Stem Cells. 2004. PMID: 15277696 Review.
-
Dendritic cell-based cancer therapy.Curr Opin Mol Ther. 2003 Aug;5(4):405-12. Curr Opin Mol Ther. 2003. PMID: 14513684 Review.
Cited by
-
Early immunisation with dendritic cells after allogeneic bone marrow transplantation elicits graft vs tumour reactivity.Br J Cancer. 2013 Mar 19;108(5):1092-9. doi: 10.1038/bjc.2013.39. Br J Cancer. 2013. PMID: 23511628 Free PMC article.
-
TNF-α and tumor lysate promote the maturation of dendritic cells for immunotherapy for advanced malignant bone and soft tissue tumors.PLoS One. 2012;7(12):e52926. doi: 10.1371/journal.pone.0052926. Epub 2012 Dec 21. PLoS One. 2012. PMID: 23300824 Free PMC article.
-
Activated dendritic cells delivered in tissue compatible biomatrices induce in-situ anti-tumor CTL responses leading to tumor regression.Oncotarget. 2016 Jun 28;7(26):39894-39906. doi: 10.18632/oncotarget.9529. Oncotarget. 2016. PMID: 27223090 Free PMC article.
-
Trial watch: Dendritic cell-based anticancer therapy.Oncoimmunology. 2014 Dec 21;3(11):e963424. doi: 10.4161/21624011.2014.963424. eCollection 2014 Nov. Oncoimmunology. 2014. PMID: 25941593 Free PMC article. Review.
-
A novel peptide targeting Clec9a on dendritic cell for cancer immunotherapy.Oncotarget. 2016 Jun 28;7(26):40437-40450. doi: 10.18632/oncotarget.9624. Oncotarget. 2016. PMID: 27250027 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical